Elinzanetant, a nonhormonal drug under development for menopause-related hot flashes, may also help relieve sleep disturbance in postmenopausal women, according to a multi-modality analysis reported by Contemporary OB/GYN. The analysis looked at how elinzanetant affected both objective and subjective measures of sleep, including sleep efficiency, total sleep time, and the number of nighttime wakings. Researchers found improvements across several sleep parameters, suggesting the drug acts through multiple pathways to address a common and troubling symptom of menopause.

Key takeaways

  • Elinzanetant improved both objective and subjective sleep measures in postmenopausal women.
  • The analysis covered sleep quality, duration, and nighttime awakenings.
  • Effects were seen alongside reductions in vasomotor symptoms (hot flashes and night sweats).
  • The drug is a neurokinin-3 (NK3) receptor antagonist, a class that may centrally regulate sleep and thermoregulation.

Understanding postmenopausal sleep disturbance

Sleep problems are common during the menopause transition and after menopause. Many women report difficulty falling asleep, waking up frequently during the night, or waking too early and not being able to return to sleep. These disturbances are often linked to vasomotor symptoms such as hot flashes and night sweats, but they can also occur independently. Sleep disruption can lead to daytime fatigue, mood changes, and reduced quality of life.

Traditional treatments include hormone therapy, which is not suitable for all women, and lifestyle modifications. Nonhormonal options are being actively studied, and elinzanetant is one of the more promising agents in clinical development.

How elinzanetant works

Elinzanetant is a selective antagonist of the neurokinin-3 (NK3) receptor. This receptor is part of the tachykinin system, which plays a role in the brain’s regulation of body temperature, mood, and sleep. By blocking NK3 receptors in the hypothalamus, elinzanetant may help stabilize the thermoregulatory center and reduce the hot flashes that often disturb sleep. Additionally, the drug may have direct effects on sleep-wake regulation, independent of its effects on temperature control.

The multi-modality analysis reported in Contemporary OB/GYN assessed both polysomnography (objective sleep recording) and patient-reported outcomes. According to the report, women taking elinzanetant showed longer total sleep time, higher sleep efficiency (the percentage of time in bed actually spent asleep), and fewer awakenings after sleep onset. Subjective reports also indicated better perceived sleep quality.

What the multi-modality analysis found

The analysis combined data from several clinical trials that used different methods to measure sleep. Objective assessments were done using wrist actigraphy or in-laboratory polysomnography. Subjective assessments included standard sleep questionnaires. Across both types of measurements, elinzanetant consistently improved sleep parameters compared with placebo. The improvements were evident as early as the first week of treatment and were sustained over the study period, which ranged from 4 to 12 weeks in different trials.

Importantly, the improvements in sleep appeared to be partly but not entirely linked to reductions in vasomotor symptoms. This suggests that elinzanetant may have a direct sleep-promoting effect, possibly by acting on brain circuits involved in sleep regulation. The report emphasizes that the multi-modality approach gives a more complete picture of how the drug affects sleep than any single measure alone.

Clinical relevance for postmenopausal women

For the millions of women who experience bothersome sleep disturbance during menopause, nonhormonal options are needed. Elinzanetant, if approved, could provide an alternative for those who cannot or choose not to take hormone therapy. The drug is currently in late-stage clinical trials, and regulatory decisions are expected in the coming months. Experts caution that while the results are encouraging, long-term safety data are still being collected.

Side effects reported in the trials included headache, dizziness, and mild gastrointestinal symptoms, but the drug was generally well tolerated. The analysis did not reveal any new safety signals related to sleep outcomes specifically.

Frequently Asked Questions

What is elinzanetant being developed for?

Elinzanetant is a nonhormonal drug primarily being developed to treat vasomotor symptoms (hot flashes and night sweats) associated with menopause. Clinical trials have also investigated its effects on sleep disturbance, which is a related and disabling symptom for many women.

How is sleep measured in these studies?

The multi-modality analysis used a combination of objective measures (polysomnography and actigraphy) and subjective patient-reported outcomes. Objective measures track sleep stages, total sleep time, and awakenings, while subjective measures capture how the woman herself rates her sleep quality. Using both gives a more robust understanding of the drug’s effects.

Is elinzanetant available for prescription now?

No, elinzanetant is not yet approved by the FDA or other regulatory agencies. It is still in clinical development, with late-stage trials ongoing. If successful, a regulatory submission and approval could follow within the next year or two.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.